Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SynKIR-110 |
Synonyms | |
Therapy Description |
SynKIR-110 comprises autologous T-lymphocytes engineered to express a killer cell immunoglobulin-like receptor (KIR)-based chimeric antigen receptor (CAR) targeting MSLN, which potentially induce killing of tumor cells expressing MSLN (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SynKIR-110 | SynKIR110|SynKIR 110 | SynKIR-110 comprises autologous T-lymphocytes engineered to express a killer cell immunoglobulin-like receptor (KIR)-based chimeric antigen receptor (CAR) targeting MSLN, which potentially induce killing of tumor cells expressing MSLN (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05568680 | Phase I | SynKIR-110 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Recruiting | USA | 0 |